Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;14(1):29990.
doi: 10.1038/s41598-024-81795-z.

Impact of body mass index on the efficacy of treatment modalities in women with refractory overactive bladder

Po-En Liu #  1 , Jiun-Chyi Hwang #  2   3   4 , Tsung-Hsien Su  2   3   4 , Hui-Hsuan Lau  5   6   7
Affiliations

Impact of body mass index on the efficacy of treatment modalities in women with refractory overactive bladder

Po-En Liu et al. Sci Rep. .

Abstract

Overactive bladder (OAB) is a prevalent condition that substantially impairs quality of life. Obesity and overweight status are recognized as significant risk factors for OAB, but their influence on treatment efficacy is not well understood. This cross-sectional study was conducted from January 2023 to October 2024 at a tertiary care hospital. Women diagnosed with refractory OAB were classified into normal weight, overweight, and obese groups according to their body mass index (BMI). Treatment options included combination pharmaceutical therapy and Botulinum toxin injections. Outcomes were assessed using the Overactive Bladder Symptom Score (OABSS) and quality of life questionnaires, administered before and 12 weeks after treatment. A total of 197 women were included in the study. Normal weight women demonstrated significant improvements in OAB symptoms and quality of life following both combination therapy and Botulinum toxin injection. Conversely, overweight and obese women showed limited improvement with pharmaceutical therapy but responded better to Botulinum toxin injections. The findings suggest that Botulinum toxin injection may be a more effective treatment modality for overweight or obese women with refractory OAB compared to pharmaceutical therapy. Normal weight women might benefit from initiating treatment with combination medication therapy.

Keywords: Body mass index; Obesity; Overactive bladder; Overweight; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Irwin, D. E. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol.50, 1306–1314 (2006). - PubMed
    1. Alsannan, B. et al. Prevalence of overactive bladder among overweight and obese women: a prospective cross-sectional cohort study. Eur. J. Obstet. Gynecol. Reprod. Biol.295, 59–64 (2024). - PubMed
    1. Krhut, J. et al. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur. J. Obstet. Gynecol. Reprod. Biol.196, 64–68 (2016). - PubMed
    1. Abrams, P. et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised double-blind dose-ranging phase 2 study (Symphony). Eur. Urol.67, 577–588 (2015). - PubMed
    1. Gratzke, C. et al. Efficacy and safety of Combination Pharmacotherapy for patients with overactive bladder: a Rapid evidence Assessment. Eur. Urol.. Eur. Urol.76, 767–779 (2019). - PubMed

Substances

LinkOut - more resources